Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped in the afternoon session after UBS raised its price target on the company's stock to $81 from $76. The financial services firm kept a ...
Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...
Engineering and scientific consulting firm Exponent Inc (NASDAQ:EXPO) shares are skyrocketing after the company reported better-than-expected first-quarter FY24 earnings. Exponent reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results